COMPARATIVE ASSESSMENT OF THE EFFICACY, SAFETY AND TOLERABILITY OF SERTACONAZOLE 2% plus ZINC PYRITHIONE 1% SHAMPOO vs KETOCONAZOLE 2% SHAMPOO IN ADULT PATIENTS WITH DANDRAFF/ SEBORRHEIC DERMATITIS OF THE SCALP

Glenmark Pharmaceuticals Ltd. Mumbai, India0 个研究点目标入组 200 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Males and non-pregnant females (with negative -human chorionic gonadotropin test). Female patients on adequate contraceptive control.
•Age: 18 to 70 years
•All newly diagnosed cases of Mild, Moderate or Severe Dandruff and /or Seborrheic dermatitis of the scalp
•Patient willing to comply with study procedures and requirements

•Pregnant and nursing women
•Patients hypersensitive to any study medications and ingredients
•Psoriasis of scalp
•Atopic dermatitis
•Tinea capitis
•Parkinson?s disease, epilepsy, facial nerve paresis, spinal cord disease
•Shoulder length or longer hair
•Topical treatment of the scalp with other antifungal medication or with corticosteroids in the last 2weeks before start of washout period.
•Systemic use of retinoids, erythromycin, tetracycline or any of its derivatives, trimethoprim/sulfamethoxazole or metronidazole within 28 days before start of washout period
•Uncontrolled diabetes
•Treatment with any other investigational drug in 4 weeks prior to study entry
•Immunocompromised states and patients with systemic infections.
•Patients with severe cardiac, hepatic, renal, or cerebrovascular disease or malignancy, chronic uncontrolled systemic diseases e.g.,hypertension, collagen disorders, etc. or any other serious medical illness.
•History of alcohol abuse
•Any other condition that in the opinion of the investigator does not justify the patient?s participation in the study.

发起方

Glenmark Pharmaceuticals Ltd. Mumbai, India